Overview
Cationic immunoliposomes are engineered nanoparticles that merge the advantages of liposomal drug carriers with targeted delivery. They consist of a phospholipid bilayer incorporating cationic lipids (e.g., DOTAP) to bind nucleic acids or drugs, coupled with antibodies or other ligands for cell-specific targeting. Developed in the 1990s, they address limitations of conventional liposomes by improving cellular uptake and reducing off-target effects. These systems are highly customizable, allowing adjustments in size (typically 80-200 nm), charge density, and ligand type. Their modular design supports diverse therapeutic payloads, from siRNA to chemotherapeutics, making them a versatile platform in precision medicine.
Physical and Chemical Properties
The physicochemical profile of cationic immunoliposomes is defined by their lipid composition. The inclusion of cationic lipids like DOTMA or DDAB confers a positive zeta potential (+20 to +50 mV), crucial for electrostatic interactions with negatively charged cell membranes. This charge also stabilizes the suspension by preventing aggregation. Particle size is controlled via extrusion or microfluidics, with polydispersity indices <0.2 indicating homogeneity. Encapsulation efficiency (>70% for most drugs) depends on the payload's hydrophobicity and preparation method (e.g., thin-film hydration vs. ethanol injection). Stability is pH-sensitive, with optimal performance at physiological pH (7.4).
Main Applications
In oncology, cationic immunoliposomes deliver chemotherapeutics (e.g., doxorubicin) to tumors by targeting overexpressed receptors like EGFR or HER2. For example, anti-HER2 immunoliposomes show 3-5x higher tumor accumulation than non-targeted versions in breast cancer models. Gene therapy applications include CRISPR-Cas9 or siRNA delivery to specific tissues, leveraging their ability to bypass lysosomal degradation. In vaccines, they enhance antigen presentation by dendritic cells. Emerging uses include theranostics, where imaging agents (e.g., quantum dots) are co-delivered with therapeutics for real-time monitoring.
Safety and Storage
Sterility is critical—lyophilized formulations reduce bacterial growth risks. Cryoprotectants (e.g., trehalose) prevent particle fusion during freezing. Leachables from lipids (e.g., oxidation products) must be monitored via HPLC. Safety assessments include hemolysis tests (<5% hemolysis at working concentrations) and cytokine release assays. PEGylation reduces opsonization, prolonging circulation time. Storage at 2-8°C maintains stability for 6-12 months; freeze-thaw cycles should be avoided. SDS-PAGE confirms antibody integrity post-conjugation.
B2B Procurement Guide
Suppliers typically offer GMP-grade batches (1-100g) with certificates of analysis detailing size, PDI, zeta potential, and endotoxin levels (<5 EU/mg). Customization options include ligand choice (e.g., scFv, Fab fragments) and payload loading. Key due diligence points: validate ligand binding affinity (SPR or flow cytometry data), assess in vitro/in vivo targeting efficacy, and review stability data under shipping conditions. Bulk pricing drops ~30% for orders >1kg. Lead times range 4-12 weeks for tailored formulations. Preferred vendors include Avanti Polar Lipids and FormuMax for research-grade, and CordenPharma for clinical-scale production.
Related Manufacturers
- 主营：嵌段共聚物、合成磷脂、荧光染料、PEG、点击化学、量子点
- 主营：甲氧基聚乙二醇、氨基聚乙二醇、羧基聚乙二醇、巯基聚乙二醇、羟基聚乙二醇、马来酰亚胺聚乙二醇、四臂聚乙二醇、荧光素聚乙二醇、叠氮聚乙二醇、硅烷聚乙二醇、炔基聚乙二醇、生物素聚乙二醇、丙烯酸酯聚乙二醇、活性脂聚乙二醇、Boc保护基团聚乙二醇、Fmoc保护基团聚乙二醇、生物素小分子PEG衍生物、甲氧基小分子PEG衍生物